AU2009322355B2 - Pharmaceutical suspension - Google Patents

Pharmaceutical suspension Download PDF

Info

Publication number
AU2009322355B2
AU2009322355B2 AU2009322355A AU2009322355A AU2009322355B2 AU 2009322355 B2 AU2009322355 B2 AU 2009322355B2 AU 2009322355 A AU2009322355 A AU 2009322355A AU 2009322355 A AU2009322355 A AU 2009322355A AU 2009322355 B2 AU2009322355 B2 AU 2009322355B2
Authority
AU
Australia
Prior art keywords
suspension
ophthalmic pharmaceutical
molecular weight
pharmaceutical suspension
typically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009322355A
Other languages
English (en)
Other versions
AU2009322355A1 (en
Inventor
Bhagwati P. Kabra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2009322355A1 publication Critical patent/AU2009322355A1/en
Application granted granted Critical
Publication of AU2009322355B2 publication Critical patent/AU2009322355B2/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG Request for Assignment Assignors: ALCON RESEARCH, LTD.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2009322355A 2008-12-05 2009-12-03 Pharmaceutical suspension Ceased AU2009322355B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12008108P 2008-12-05 2008-12-05
US61/120,081 2008-12-05
PCT/US2009/066570 WO2010065730A2 (en) 2008-12-05 2009-12-03 Pharmaceutical suspension

Publications (2)

Publication Number Publication Date
AU2009322355A1 AU2009322355A1 (en) 2010-06-10
AU2009322355B2 true AU2009322355B2 (en) 2015-11-05

Family

ID=41562672

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009322355A Ceased AU2009322355B2 (en) 2008-12-05 2009-12-03 Pharmaceutical suspension

Country Status (17)

Country Link
US (1) US9707173B2 (enExample)
EP (1) EP2364137B1 (enExample)
JP (1) JP5661640B2 (enExample)
AR (1) AR074423A1 (enExample)
AU (1) AU2009322355B2 (enExample)
CA (1) CA2745123C (enExample)
CY (1) CY1119038T1 (enExample)
DK (1) DK2364137T3 (enExample)
ES (1) ES2630037T3 (enExample)
HR (1) HRP20170959T1 (enExample)
HU (1) HUE034662T2 (enExample)
LT (1) LT2364137T (enExample)
PL (1) PL2364137T3 (enExample)
PT (1) PT2364137T (enExample)
SI (1) SI2364137T1 (enExample)
TW (1) TW201023912A (enExample)
WO (1) WO2010065730A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011008680A (es) * 2009-03-03 2011-09-08 Alcon Res Ltd Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos.
US8912236B2 (en) 2009-03-03 2014-12-16 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
JP2013535451A (ja) * 2010-07-21 2013-09-12 アルコン リサーチ， リミテッド 増強された溶解度特徴を有する薬学的組成物
EP2601187A1 (en) 2010-08-05 2013-06-12 Conrig Pharma ApS Deuterated tandospirone derivatives as 5-ht1a receptor agonists
US9630909B2 (en) 2013-06-27 2017-04-25 Mylan Laboratories Ltd Process for the preparation of nepafenac
JP6279395B2 (ja) * 2014-05-01 2018-02-14 東亜薬品株式会社 ブリンゾラミド懸濁性点眼液組成物の製造方法
US11458041B2 (en) 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
CN108434116B (zh) * 2017-02-16 2021-05-11 人福普克药业（武汉）有限公司 贝萨罗汀软胶囊及其制备方法
AU2018298855B2 (en) 2017-07-14 2024-07-18 Janssen Pharmaceutica Nv Long-acting formulations
GR1009419B (el) * 2017-11-07 2018-12-14 Φαρματεν Αβεε Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου
TWI798452B (zh) * 2019-06-17 2023-04-11 晶碩光學股份有限公司 隱形眼鏡產品
CN113018271B (zh) * 2019-12-25 2022-08-09 四川科瑞德制药股份有限公司 一种坦度螺酮药物组合物及其制备方法和用途
DK3861985T3 (da) 2020-02-06 2023-07-24 Ocular Therapeutix Inc Sammensætninger og fremgangsmåder til behandling af øjensygdomme
CA3177005A1 (en) 2020-04-27 2021-11-04 Michael Goldstein Methods of treating allergic conjunctivitis
US20220105100A1 (en) * 2020-10-05 2022-04-07 Somerset Therapeutics, Llc Safe brinzolamide and brimonidine compositions with enhanced benzalkonium chloride content
US20220105101A1 (en) 2020-10-05 2022-04-07 Somerset Therapeutics, Llc Efficient brinzolamide and brimonidine compositions
EP4565242A1 (en) * 2023-05-11 2025-06-11 Akums Drugs And Pharmaceuticals Limited Benzalkonium chloride free ophthalmic formulation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856919A (en) * 1970-06-08 1974-12-24 Burton Parsons Chemicals Inc Ophthalmic solution
US4409205A (en) * 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US5624962A (en) * 1993-04-16 1997-04-29 Wakamoto Pharmaceutical Co., Ltd. Aqueous drug composition having property of reversible thermosetting gelation
US20030165568A1 (en) * 2000-05-15 2003-09-04 Giuseppe Colombo Stabilized steroidal suspension
US20060172969A1 (en) * 2000-08-08 2006-08-03 Wakamoto Pharmaceutical Co., Ltd. Aqueous pharmaceutical compositions
US20070173538A1 (en) * 2005-12-23 2007-07-26 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3931319A (en) 1974-10-29 1976-01-06 Millmaster Onyx Corporation Capped polymers
US4027020A (en) 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4525346A (en) 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4836986A (en) 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US5037647A (en) 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
US5461081A (en) 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5145643A (en) 1990-01-05 1992-09-08 Allergan, Inc. Nonoxidative ophthalmic compositions and methods for preserving and using same
US5206267A (en) 1991-05-09 1993-04-27 Morton Shulman Pain controlling composition and method of preparation
US5338732A (en) 1991-06-18 1994-08-16 Bristol-Myers Squibb Company Megestrol acetate formulation
US5932572A (en) 1992-02-21 1999-08-03 Alcon Laboratories, Inc. Topical anti-glaucoma compositions
US5300287A (en) 1992-11-04 1994-04-05 Alcon Laboratories, Inc. Polymeric antimicrobials and their use in pharmaceutical compositions
EP0782850A4 (en) 1994-10-13 1998-03-04 Wakamoto Pharma Co Ltd LYOPHILIZED PREPARATION FOR PRODUCING A REVERSIBLE THERMOGELING MEDICINAL WATER-BASED
AU718199B2 (en) 1996-12-13 2000-04-06 Alcon Laboratories, Inc. Use of low molecular weight amino alcohols in ophthalmic compositions
JPH10287552A (ja) 1997-04-11 1998-10-27 Kobayashi Seiyaku Kogyo Kk 滅菌されたアシクロビル水性懸濁点眼剤及びその製造方法
ATE225392T1 (de) 1997-07-29 2002-10-15 Alcon Lab Inc Konditionierungslösungen für die pflege von harten kontaktlinsen
AU6870800A (en) * 1999-09-06 2001-04-10 Ono Pharmaceutical Co. Ltd. Preventive and therapeutic agents for eye diseases
PT1214056E (pt) 1999-09-24 2004-02-27 Alcon Inc Formulacoes em suspensao topica que contem ciprofloxacina e dexametasona
JP2004504357A (ja) 2000-07-26 2004-02-12 アルコン，インコーポレイテッド ポリマー性懸濁化剤を含有しない薬学的懸濁組成物
US20040256749A1 (en) 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6743439B1 (en) * 2001-06-27 2004-06-01 Alcon, Inc. Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
BR0212898A (pt) 2001-09-21 2004-10-13 Alcon Inc Método de tratamento de infecções do ouvido médio
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
US20050025791A1 (en) 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
PT1638941E (pt) 2003-05-22 2010-08-24 Abbott Lab Inibidores de quinases de indazole, benzisoxazole e benzisotiazole
US20040235892A1 (en) 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
CA2562356A1 (en) 2004-04-08 2005-10-27 Retmed Pty Ltd Treatment of ophthalmic conditions with mineralcorticoids
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
ES2322200T3 (es) 2005-05-10 2009-06-17 Alcon, Inc. Formulaciones en suspension que comprenden un principio activo, un tensioactivo poloxamero o meroxapol y un glicol, su uso para la fabricacion de un medicamento para tratar trastornos oftalmicos.
CN101175476B (zh) 2005-05-10 2011-11-16 爱尔康公司 包含眼科药物、泊洛沙明和二醇张力调节剂的眼科混悬剂，所述组合物用于生产治疗眼科病症的药物的用途
JP2009521493A (ja) 2005-12-23 2009-06-04 アルコン，インコーポレイテッド 眼への受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の送達のための医薬製剤
US20070249546A1 (en) 2006-04-22 2007-10-25 Sawaya Assad S Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them
US8071544B2 (en) * 2006-12-18 2011-12-06 Althea Technologies, Inc. Crystallized recombinant human growth factor formulations
JP2010534201A (ja) 2007-07-20 2010-11-04 アルコン，インコーポレイテッド 受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の目への送達のための医薬製剤
PL2072564T3 (pl) 2007-12-19 2013-12-31 Sika Tech Ag Jednoskładnikowa, utwardzająca się pod wpływem wilgoci pianka polimerowa
JP5155767B2 (ja) 2008-08-04 2013-03-06 国立大学法人大阪大学 ガス検知素子
MX2011008680A (es) 2009-03-03 2011-09-08 Alcon Res Ltd Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856919A (en) * 1970-06-08 1974-12-24 Burton Parsons Chemicals Inc Ophthalmic solution
US4409205A (en) * 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US5624962A (en) * 1993-04-16 1997-04-29 Wakamoto Pharmaceutical Co., Ltd. Aqueous drug composition having property of reversible thermosetting gelation
US20030165568A1 (en) * 2000-05-15 2003-09-04 Giuseppe Colombo Stabilized steroidal suspension
US20060172969A1 (en) * 2000-08-08 2006-08-03 Wakamoto Pharmaceutical Co., Ltd. Aqueous pharmaceutical compositions
US20070173538A1 (en) * 2005-12-23 2007-07-26 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE

Also Published As

Publication number Publication date
US20100144719A1 (en) 2010-06-10
ES2630037T3 (es) 2017-08-17
PL2364137T3 (pl) 2017-09-29
CA2745123C (en) 2018-11-13
SI2364137T1 (sl) 2017-07-31
CY1119038T1 (el) 2018-01-10
WO2010065730A3 (en) 2011-04-14
EP2364137A2 (en) 2011-09-14
JP5661640B2 (ja) 2015-01-28
JP2012511009A (ja) 2012-05-17
LT2364137T (lt) 2017-06-26
TW201023912A (en) 2010-07-01
EP2364137B1 (en) 2017-03-29
AU2009322355A1 (en) 2010-06-10
WO2010065730A2 (en) 2010-06-10
AR074423A1 (es) 2011-01-19
HUE034662T2 (en) 2018-02-28
HRP20170959T1 (hr) 2017-09-22
DK2364137T3 (en) 2017-07-10
PT2364137T (pt) 2017-07-10
US9707173B2 (en) 2017-07-18
CA2745123A1 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
AU2009322355B2 (en) Pharmaceutical suspension
JP2012511009A5 (enExample)
TW201100103A (en) Aqueous pharmaceutical compositions containing borate-polyol complexes
JP6353365B2 (ja) 水性液剤
JP2010265261A (ja) レボカバスチン懸濁型点眼剤
RU2601115C2 (ru) Офтальмологическая композиция с повышающей вязкость системой, содержащей два различных средства повышения вязкости
AU2012245538B2 (en) Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents
AU2010236505B2 (en) Aqueous ophthalmic compositions containing anionic therapeutic agents
US10751295B2 (en) Compositions and methods for the removal of ear wax

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: NOVARTIS AG

Free format text: FORMER OWNER(S): ALCON RESEARCH, LTD.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired